Full Text
The Cost-Effectiveness of 2nd Line Crizotinib in EML4-Alk Rearranged Advanced NSCLC in Ontario

Abstract

Authors

S. Djalalov D.M. Graham J. Beca J.S. Hoch M.S. Tsao J.C. Cutz N. Leighl

Back to Volume 17, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×